Atreca is a biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-Âcancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atrecaâs proprietary Immune Repertoire CaptureÂŽ technology profiles a patientâs immune response at the single-Âcell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. Source
No articles found.
ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...
ChemoCentryx is a biopharmaceutical company foc...
The next evolution in DNA-based diagnostics. MicroGen Vet is the exclusive reselle...
The next evolution in DNA-based diagnostics. Mi...
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading glo...
WuXi Biologics (stock code: 2269.HK), a Hong Ko...
Founded 20 years ago, Seattle Genetics was built on a foundation of scientific inn...
Founded 20 years ago, Seattle Genetics was buil...
YiLo Life uses organic methods and the finest ingredients to create cannabis produ...
YiLo Life uses organic methods and the finest i...
Terumo Corporation is a manufacturer and supplier of pharmaceuticals and medical t...
Terumo Corporation is a manufacturer and suppli...
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight mu...
Gritstone Oncology is developing tumor-specific...
Join the National Investor Network and get the latest information with your interests in mind.